A groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with ...

Colon cancer rates are surging worldwide, especially among younger and relatively healthy people, making it more important ...

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

Colon cancer screening is only effective if you complete the test. With 53,000 Americans expected to die from colon cancer in ...

FRUZAQLA is not chemotherapy. It is a targeted therapy that affects vascular endothelial growth factor (VEGF) receptors, ...

Mainz Biomed’s stool-based ColoAlert test is designed to detect colorectal cancer tumor DNA to aid in identifying colorectal cancer in early stages. Through polymerase chain reaction (PCR) technology, ...

Mainz Biomed (MYNZ) announced an agreement with Quest Diagnostics (DGX), a leading provider of diagnostic information services, to support ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

This provocative study demonstrates that biological age, which can be evaluated by a blood test, is associated with a higher ...

Special Report: Predictive cancer diagnostics company Rhythm Biosciences (ASX:RHY) is ending 2024 on a high reporting it had ...

Improvements in cancer prevention and screening have averted more deaths than treatment advances over the past 45 years.

Microbes living in our guts help us digest food by reshaping the bile acids that our livers produce for breaking down fats.